دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Diagnosis of GORD: is the ‘grey area’ expanding?
Frank Zerbib
doi : 10.1136/gutjnl-2021-324237
Gut 2021;70:2221-2222.
Are sugar-sweetened beverages contributing to the rising occurrence of colorectal cancer in young adults?
Neil Murphy, Peter T Campbell, Marc J Gunter
doi : 10.1136/gutjnl-2021-324614
Gut 2021;70:2222-2223.
Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies
Ji Young Bang, Thomas J Ward, Shady Guirguis, Konrad Krall, Francisco Contreras, Nirag Jhala, Udayakumar Navaneethan, Robert H Hawes, Shyam Varadarajulu
doi : 10.1136/gutjnl-2021-324495
Gut 2021;70:2224-2226.
COVID-19 transmission following outpatient endoscopy during pandemic acceleration phase involving SARS-CoV-2 VOC 202012/01 variant in UK
Bu'Hussain Hayee, The SCOTS II Project group, Pradeep Bhandari, Colin J Rees, Ian Penman
doi : 10.1136/gutjnl-2021-324354
Gut 2021;70:2227-2229.
Validation of the Lyon classification for GORD diagnosis: acid exposure time assessed by prolonged wireless pH monitoring in healthy controls and patients with erosive oesophagitis
Radu-Ionut Rusu, Mark R Fox, Emily Tucker, Sebastian Zeki, Jason M Dunn, Jafar Jafari, Fiona Warburton, Terry Wong
doi : 10.1136/gutjnl-2020-323798
Gut 2021;70:2230-2237.
Acid exposure time (AET) from ambulatory pH studies and reflux oesophagitis are independent measurements used by the Lyon classification to diagnose GORD. This study aimed to validate AET reference ranges and diagnostic thresholds by analysis of 96-hour wireless pH studies from healthy, asymptomatic controls (HCs) and patients with and without oesophagitis.
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
Shumei Song, Qiongrong Chen, Yuan Li, Guang Lei, Ailing Scott, Longfei Huo, Cordelia Y Li, Jeannelyn Santiano Estrella, Arlene Correa, Melissa Pool Pizzi, Lang Ma, Jiankang Jin, Bin Liu, Ying Wang, Lianchun Xiao, Wayne L Hofstetter, Jeffrey H Lee, Brian Weston, Manoop Bhutani, Namita Shanbhag, Randy L Johnson, Boyi Gan, Shaozhong Wei, Jaffer A Ajani
doi : 10.1136/gutjnl-2020-321175
Gut 2021;70:2238-2248.
Gastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis. The cancer stem cells (CSCs) and antiapoptotic pathways often confer therapy resistance. We sought to elucidate the antitumour action of a BCL-2 inhibitor, AT101 in GEC in vitro, in vivo and in a clinical trial.
Prostaglandin E2 receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation
Yi Rang Na, Daun Jung, Michelle Stakenborg, Hyeri Jang, Gyo Jeong Gu, Mi Reu Jeong, Soo Youn Suh, Hak Jae Kim, Yoon Hey Kwon, Tae Sik Sung, Seung Bum Ryoo, Kyu Joo Park, Jong Pil Im, Ji Yong Park, Yun Sang Lee, Heonjong Han, Boyoun Park, Sungwook Lee, Daesik Kim, Ho Su Lee, Isabelle Cleynen, Gianluca Matteoli, Seung Hyeok Seok
doi : 10.1136/gutjnl-2020-322146
Gut 2021;70:2249-2260.
Dysfunctional resolution of intestinal inflammation and altered mucosal healing are essential features in the pathogenesis of inflammatory bowel disease (IBD). Intestinal macrophages are vital in the process of inflammation resolution, but the mechanisms underlying their mucosal healing capacity remain elusive.
Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis
Luoyan Ai, Yimeng Ren, Mingming Zhu, Shiyuan Lu, Yun Qian, Zhaofei Chen, Antao Xu
doi : 10.1136/gutjnl-2020-321094
Gut 2021;70:2261-2272.
As a canonical membrane tethering factor, the function of synbindin has been expanding and indicated in immune response. Here, we investigated the role of synbindin in the regulation of toll-like receptor 4 (TLR4) signalling and macrophage response to microbiota during colitis.
Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis
Andrea C Masi, Nicholas D Embleton, Christopher A Lamb, Gregory Young, Claire L Granger, Julia Najera, Daniel P Smith, Kristi L Hoffman, Joseph F Petrosino, Lars Bode, Janet E Berrington, Christopher J Stewart
doi : 10.1136/gutjnl-2020-322771
Gut 2021;70:2273-2282.
Necrotising enterocolitis (NEC) is a devastating intestinal disease primarily affecting preterm infants. The underlying mechanisms are poorly understood: mother’s own breast milk (MOM) is protective, possibly relating to human milk oligosaccharide (HMO) and infant gut microbiome interplay. We investigated the interaction between HMO profiles and infant gut microbiome development and its association with NEC.
Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways
María Arnoriaga-Rodríguez, Jordi Mayneris-Perxachs, Oren Contreras-Rodríguez, Aurelijus Burokas, Juan-Antonio Ortega-Sanchez, Gerard Blasco, Claudia Coll, Carles Biarnés, Anna Castells-Nobau, Josep Puig, Josep Garre-Olmo, Rafel Ramos, Salvador Pedraza, Ramon Brugada, Joan C Vilanova, Joaquín Serena, Jordi Barretina, Jordi Gich, Vicente Pérez-Brocal, Andrés Moya, Xavier Fernández-Real, Lluis Ramio-Torrentà, Reinald Pamplona, Joaquim Sol, Mariona Jové, Wifredo Ricart, Manuel Portero-Otin, Rafael Maldonado, Jose Manuel Fernández-Real
doi : 10.1136/gutjnl-2020-323371
Gut 2021;70:2283-2296.
Inhibitory control (IC) is critical to keep long-term goals in everyday life. Bidirectional relationships between IC deficits and obesity are behind unhealthy eating and physical exercise habits.
Novel scheme for non-invasive gut bioinformation acquisition with a magnetically controlled sampling capsule endoscope
Zhen Ding, Weijun Wang, Kun Zhang, Fanhua Ming, Tianyi Yangdai, Tao Xu, Huiying Shi, Yuhui Bao, Hailing Yao, Hangyu Peng, Chaoqun Han, Weiwei Jiang, Jun Liu, Xiaohua Hou, Rong Lin
doi : 10.1136/gutjnl-2020-322465
Gut 2021;70:2297-2306.
Intestinal flora and metabolites are associated with multiple systemic diseases. Current approaches for acquiring information regarding microbiota/metabolites have limitations. We aimed to develop a precise magnetically controlled sampling capsule endoscope (MSCE) for the convenient, non-invasive and accurate acquisition of digestive bioinformation for disease diagnosis and evaluation.
Colorectal cancer risk following polypectomy in a multicentre, retrospective, cohort study: an evaluation of the 2020 UK post-polypectomy surveillance guidelines
Amanda J Cross, Emma C Robbins, Kevin Pack, Iain Stenson, Bhavita Patel, Matthew D Rutter, Andrew M Veitch, Brian P Saunders, Stephen W Duffy, Kate Wooldrage
doi : 10.1136/gutjnl-2020-323411
Gut 2021;70:2307-2320.
Colonoscopy surveillance aims to reduce colorectal cancer (CRC) incidence after polypectomy. The 2020 UK guidelines recommend surveillance at 3?years for ‘high-risk’ patients with ?2 premalignant polyps (PMPs), of which ?1 is ‘advanced’ (serrated polyp (or adenoma) ?10?mm or with (high-grade) dysplasia); ?5 PMPs; or ?1 non-pedunculated polyp ?20?mm; ‘low-risk’ patients without these findings are instead encouraged to participate in population-based CRC screening. We examined the appropriateness of these risk classification criteria and recommendations.
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers
Han-Mo Chiu, Grace Hsiao-Hsuan Jen, Ying-Wei Wang, Jean Ching-Yuan Fann, Chen-Yang Hsu, Ya-Chung Jeng, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Sam Li-Sheng Chen, Wen-Feng Hsu, Yi-Chia Lee, Ming-Shiang Wu, Chien-Yuan Wu, Yann-Yuh Jou, Tony Hsiu-Hsi Chen
doi : 10.1136/gutjnl-2020-322545
Gut 2021;70:2321-2329.
To measure the effects of faecal immunochemical test (FIT) for colorectal cancer (CRC) screening on overall and site-specific long-term effectiveness of population-based organised service screening.
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women
Jinhee Hur, Ebunoluwa Otegbeye, Hee-Kyung Joh, Katharina Nimptsch, Kimmie Ng, Shuji Ogino, Jeffrey A Meyerhardt, Andrew T Chan, Walter C Willett, Kana Wu, Edward Giovannucci, Yin Cao
doi : 10.1136/gutjnl-2020-323450
Gut 2021;70:2330-2336.
Sugar-sweetened beverage (SSB) consumption had substantially increased across successive US birth cohorts until 2000, and adolescents and young adults under age 50 years have the highest consumption. However, the link between SSBs and early-onset colorectal cancer (EO-CRC) remains unexamined.
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
Valentina Svicher, Romina Salpini, Lorenzo Piermatteo, Luca Carioti, Arianna Battisti, Luna Colagrossi, Rossana Scutari, Matteo Surdo, Valeria Cacciafesta, Andrea Nuccitelli, Navjyot Hansi, Francesca Ceccherini Silberstein, Carlo Federico Perno, Upkar S Gill, Patrick T F Kennedy
doi : 10.1136/gutjnl-2020-323300
Gut 2021;70:2337-2348.
The involvement of HBV DNA integration in promoting hepatocarcinogenesis and the extent to which the intrahepatic HBV reservoir modulates liver disease progression remains poorly understood. We examined the intrahepatic HBV reservoir, the occurrence of HBV DNA integration and its impact on the hepatocyte transcriptome in hepatitis B ‘e’ antigen (HBeAg)-negative chronic hepatitis B (CHB).
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)
Ming-Lung Yu, Chung-Feng Huang, Yu-Ju Wei, Wen-Yi Lin, Yi-Hung Lin, Po-Yao Hsu, Cheng-Ting Hsu, Ta Wei Liu, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Tzu-Sui Hung, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Ming-Yen Hsieh, Szu-Chia Chen, Jee-Fu Huang, Jer-Ming Chang, Yi-Wen Chiu, Chia-Yen Dai, Shang-Jyh Hwang, Wan-Long Chuang
doi : 10.1136/gutjnl-2020-323277
Gut 2021;70:2349-2358.
HCV prevails in uremic haemodialysis patients. The current study aimed to achieve HCV microelimination in haemodialysis centres through a comprehensive outreach programme.
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
Marta B Afonso, Pedro M Rodrigues, Miguel Mateus-Pinheiro, André L Simão, Maria M Gaspar, Amine Majdi, Enara Arretxe, Cristina Alonso, Alvaro Santos-Laso, Raul Jimenez-Agüero, Emma Eizaguirre, Luis Bujanda, Maria Jesus Pareja, Jesus M Banales, Vlad Ratziu, Jeremie Gautheron, Rui E Castro, Cecília M P Rodrigues
doi : 10.1136/gutjnl-2020-321767
Gut 2021;70:2359-2372.
Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3 signalling in the pathogenesis of human and experimental NAFLD.
Alternative splicing of viral transcripts: the dark side of HBV
Dina Kremsdorf, Bouchra Lekbaby, Pierre Bablon, Jules Sotty, Jérémy Augustin, Aurélie Schnuriger, Jonathan Pol, Patrick Soussan
doi : 10.1136/gutjnl-2021-324554
Gut 2021;70:2373-2382.
Regulation of alternative splicing is one of the most efficient mechanisms to enlarge the proteomic diversity in eukaryotic organisms. Many viruses hijack the splicing machinery following infection to accomplish their replication cycle. Regarding the HBV, numerous reports have described alternative splicing events of the long viral transcript (pregenomic RNA), which also acts as a template for viral genome replication. Alternative splicing of HBV pregenomic RNAs allows the synthesis of at least 20 spliced variants. In addition, almost all these spliced forms give rise to defective particles, detected in the blood of infected patients. HBV-spliced RNAs have long been unconsidered, probably due to their uneasy detection in comparison to unspliced forms as well as for their dispensable role during viral replication. However, recent data highlighted the relevance of these HBV-spliced variants through (1) the trans-regulation of the alternative splicing of viral transcripts along the course of liver disease; (2) the ability to generate defective particle formation, putative biomarker of the liver disease progression; (3) modulation of viral replication; and (4) their intrinsic propensity to encode for novel viral proteins involved in liver pathogenesis and immune response. Altogether, tricky regulation of HBV alternative splicing may contribute to modulate multiple viral and cellular processes all along the course of HBV-related liver disease.
Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine
Daniel So, Peter R Gibson, Jane G Muir, Chu K Yao
doi : 10.1136/gutjnl-2021-324891
Gut 2021;70:2383-2394.
Clinical guidelines in the use of fibre supplementation for patients with IBS provide one-size-fits-all advice, which has limited value. This narrative review addresses data and concepts around the functional characteristics of fibre and subsequent physiological responses induced in patients with IBS with a view to exploring the application of such knowledge to the precision use of fibre supplements. The key findings are that first, individual fibres elicit highly distinct physiological responses that are associated with their functional characteristics rather than solubility. Second, the current evidence has focused on the use of fibres as a monotherapy for IBS symptoms overall without attempting to exploit these functional characteristics to elicit specific, symptom-targeted effects, or to use fibre types as adjunctive therapies. Personalisation of fibre therapies can therefore target several therapeutic goals. Proposed goals include achieving normalisation of bowel habit, modulation of gut microbiota function towards health and correction of microbial effects of other dietary therapies. To put into perspective, bulking fibres that are minimally fermented can offer utility in modulating indices of bowel habit; slowly fermented fibres may enhance the activities of the gut microbiota; and the combination of both fibres may potentially offer both benefits while optimising the activities of the microbiota throughout the different regions of the colon. In conclusion, understanding the GI responses to specific fibres, particularly in relation to the physiology of the individual, will be the future for personalising fibre therapy for enhancing the personalised management of patients with IBS.
GI highlights from the literature
Philip J Smith
doi : 10.1136/gutjnl-2021-326360
Gut 2021;70:2395-2396.
Intraductal bile duct stents should be prioritised for removal during the pandemic
Wafaa Ahmed, Deepak Joshi, Phillip Harrison, David Reffitt, John Devlin
doi : 10.1136/gutjnl-2021-324105
Gut 2021;70:2397.
PPIs and anti-TNF in patients with IBD: a forbidden combination?
Judith Wellens, João Sabino, Séverine Vermeire
doi : 10.1136/gutjnl-2021-324040
Gut 2021;70:2397-2398.
Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
Colleen GC McGregor, Alex Adams, Ross Sadler, Carolina V Arancibia-Cárcamo, Rebecca Palmer, Tim Ambrose, Oliver Brain, Alissa Walsh, Paul Klenerman, Simon PL Travis, Nicholas M Croft, James O Lindsay, Jack Satsangi
doi : 10.1136/gutjnl-2021-324116
Gut 2021;70:2398-2400.
Artificial intelligence in EUS for autoimmune pancreatitis: bias and real life
Matteo Tacelli, Piera Zaccari, Gabriele Capurso, Paolo Giorgio Arcidiacono
doi : 10.1136/gutjnl-2021-324338
Gut 2021;70:2400-2401.
Large volume paracentesis: to do or where to do?
Lucia Macken, Naaventhan Palaniyappan, Sumita Verma, Guruprasad Aithal
doi : 10.1136/gutjnl-2021-324249
Gut 2021;70:2401-2402.
Uphill or downhill bleeding?
Zillah Cargill, Tamsin Cargill, Brian Lei, Noor Bekkali, James East, Jonathan Marshall
doi : 10.1136/gutjnl-2020-322298
Gut 2021;70:2282-2348.
